Evidence map›Paper›PMID 34797531›Full record

Trial reportInternational journal of hematology2022

Safety and efficacy of durvalumab with R-CHOP or R

Grzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas S Larsen, Krish Patel, Ulrich Jäger, Robert F Manges, Lorenz Trümper, Hele Everaus, Nagesh Kalakonda and 10 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 7 countries.

Grzegorz S NowakowskiDivision of Hematology, Mayo Clinic Rochester, 200 1st St SW, Rochester, MN, 55902, USA. nowakowski.grzegorz@mayo.edu.
Wolfgang WillenbacherInternal Medicine, Hematology and Oncology Department, Innsbruck Medical University, Innsbruck, Austria.
Richard GreilSalzburg Cancer Research Institute and Cancer Cluster, Paracelsus Medical University Salzburg, Salzburg, Austria.
Thomas S LarsenDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Krish PatelSwedish Cancer Institute Hematology and Oncology Department, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA.
Ulrich JägerDivision of Hematology and Hemostseology, Medical University of Vienna, Vienna, Austria.
Robert F MangesParkview Health, Parkview Cancer Institute, Hematology Tumor Site, Fort Wayne, IN, USA.
Lorenz TrümperDepartment of Hematology-Oncology, Universitätsmedizin Göttingen, Göttingen, Germany.
Hele EverausHaematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia.
Nagesh KalakondaUniversity of Liverpool and The Clatterbridge Cancer Centre, Liverpool, UK.
Peter BrownRigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Judit Meszaros JørgensenAarhus University Hospital, Aarhus, Denmark.
David CunninghamThe Royal Marsden Hospital, The Institute of Cancer Research, Sutton, Surrey, UK.
Justine Dell'AringaCelgene International, Boudry, Switzerland.
Brian FoxCelgene International, Boudry, Switzerland.
Neus Domper RubioCelgene International, Boudry, Switzerland.
Nurgul KilavuzCelgene International, Boudry, Switzerland.
Marie-Laure CasadebaigCelgene International, Boudry, Switzerland.
Oliver ManzkeCelgene International, Boudry, Switzerland.
Javier MunozBanner MD Anderson Cancer Center, Phoenix, AZ, USA.
Bristol-Myers Squibb (Switzerland) · CHAarhus University Hospital · DKBanner MD Anderson Cancer CenterClatterbridge Cancer Centre NHS Foundation Trust · GBCopenhagen University Hospital · DKInnsbruck Medical University · ATMayo Clinic · USMedical University of Vienna · ATOdense University Hospital · DKParacelsus Medical University · ATParkview Health · USRoyal Marsden Hospital · GBSwedish Medical Center · USTartu University Hospital · EEUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R

Indexed as

AgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrednisoneRituximabTreatment OutcomeVincristineAntibodies, MonoclonalCyclophosphamideDoxorubicindurvalumabPrednisoneR-CHOP protocolRituximabVincristineDiffuse large B-cell lymphomaDurvalumabHigh riskR-CHOP

Identifiers

PMID34797531
OpenAlexW3211913577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.